Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Age-related Wet Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT04757636
What this trial is testing

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
Opthea Limited 998
Post-approval studies (Phase 4)Study completedNCT02305238
What this trial is testing

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Who this might be right for
Wet Macular Degeneration
Bayer 288
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Not applicableStudy completedNCT01447043
What this trial is testing

Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)

Who this might be right for
Ophthalmology, Macular Degeneration
Bayer 2,609
Testing effectiveness (Phase 2)Study completedNCT01134055
What this trial is testing

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
GlaxoSmithKline 510
Testing effectiveness (Phase 2)Study completedNCT01849692
What this trial is testing

ESBA1008 Microvolume Study

Who this might be right for
Exudative Age-Related Macular Degeneration
Alcon Research 107
Post-approval studies (Phase 4)Looking for participantsNCT06875245
What this trial is testing

Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals

Who this might be right for
Wet Age-related Macular Degeneration
Faculty Hospital Kralovske Vinohrady 100
Testing effectiveness (Phase 2)Study completedNCT01414153
What this trial is testing

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Who this might be right for
Exudative Age-related Macular Degeneration
Lpath, Inc. 158
Testing effectiveness (Phase 2)Study completedNCT03626636
What this trial is testing

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Who this might be right for
Dry Age-related Macular Degeneration
Allegro Ophthalmics, LLC 42
Testing effectiveness (Phase 2)Ended earlyNCT00089830
What this trial is testing

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
Genaera Corporation 120
Large-scale testing (Phase 3)Study completedNCT04857177
What this trial is testing

Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Who this might be right for
Neovascular(Wet) Age Related Macular Degeneration
Chong Kun Dang Pharmaceutical 312
Not applicableActive Not RecruitingNCT06717139
What this trial is testing

Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD

Who this might be right for
Retinal DiseasesMacular DegenerationNeovascular (Wet) Age-Related Macular Degeneration
St. Erik Eye Hospital 220
Large-scale testing (Phase 3)Looking for participantsNCT07064759
What this trial is testing

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics 480
Testing effectiveness (Phase 2)Study completedNCT03345082
What this trial is testing

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Opthea Limited 366
Large-scale testing (Phase 3)Study completedNCT00891735
What this trial is testing

Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

Who this might be right for
Age-related Macular Degeneration
Genentech, Inc. 1,097
Very early researchNot Yet RecruitingNCT06888492
What this trial is testing

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

Who this might be right for
Wet Age-related Macular Degeneration (wAMD)Wet Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 8
Large-scale testing (Phase 3)Study completedNCT05345236
What this trial is testing

Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Who this might be right for
Wet Age-related Macular Degeneration
Qilu Pharmaceutical Co., Ltd. 366
Testing effectiveness (Phase 2)Study completedNCT01749891
What this trial is testing

A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
Allegro Ophthalmics, LLC 25
Post-approval studies (Phase 4)Study completedNCT02581891
What this trial is testing

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Who this might be right for
Macular Degeneration
Bayer 287
Early research (Phase 1)Study completedNCT05903794
What this trial is testing

EXG102-031 in Patients With wAMD (Everest)

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Exegenesis Bio 12
Next Page